{"id":"W2776736524","doi":"10.1016/s1470-2045(17)30912-9","title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"National Center for Advancing Translational Sciences; BC Cancer Agency; University of British Columbia","keywords":"Brentuximab vedotin; Medicine; Bendamustine; Anaplastic large-cell lymphoma; Internal medicine; Oncology; Regimen; Lymphoma; Chemotherapy; Chemotherapy regimen; Refractory (planetary science); Surgery; CD30; Rituximab","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005708588,0.0002289232,0.0007722151,0.00009806819,0.0002135441,0.00006984117,0.000565386,0.0001847455,0.0004370606],"category_scores_gemma":[0.0009177689,0.0001401886,0.00009916503,0.00006119031,0.0002113153,0.0001553252,0.000158851,0.000177906,0.00008081919],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001303454,"about_ca_system_score_gemma":0.0004757196,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005507993,"about_ca_topic_score_gemma":0.00115307,"domain_scores_codex":[0.9982164,0.0002393704,0.0004367727,0.000407917,0.0002607765,0.0004387679],"domain_scores_gemma":[0.9978697,0.0004222741,0.0004279222,0.001048491,0.00008665753,0.0001449221],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4206067,0.05877323,0.0124442,0.00005710738,0.0005324511,0.004338177,0.002519042,0.00001894156,0.001314849,0.0006943805,0.007490329,0.4912106],"study_design_scores_gemma":[0.7107584,0.01342074,0.06275389,0.0001255117,0.0002937738,0.0002183848,0.0003036911,0.001351452,0.0006479439,0.00007246681,0.2098247,0.0002290271],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762187,0.0001495674,0.000004164636,0.01070439,0.002001161,0.0009492835,0.00004473271,0.00006744061,0.009860534],"genre_scores_gemma":[0.9945921,0.0003630569,0.0006448728,0.001285513,0.002144681,0.0001605784,0.0001067531,0.00002835832,0.0006740591],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4909815,"threshold_uncertainty_score":0.5716726,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1513362077320565,"score_gpt":0.4312362036939666,"score_spread":0.2798999959619101,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}